Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Gabapentin is an anticonvulsant medication used in the management of peripheral neuropathic pains, postherpetic neuralgia, and partial-onset seizures. Gabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) that was first approved for use in the United States in 1993.
- Mechanism
- Curator reviewed · 12 references
The precise mechanism through which gabapentin exerts its therapeutic effects is unclear. The primary mode of action appears to be at the auxillary α2δ-1 subunit of voltage-gated calcium channels (though a low affinity for the α2δ-2 subunit has also been reported). The major function of these subunits is to facilitate the movement of pore-forming α1 subunits of calcium channels from the endoplasmic reticulum to the cell membrane of pre-synaptic neurons. There is evidence that chronic pain states can cause an increase in the expression of α2δ subunits and that these changes correlate with hyperalgesia. Gabapentin appears to inhibit the action of α2δ-1 subunits, thus decreasing the density of pre-synaptic voltage-gated calcium channels and subsequent release of excitatory neurotransmitters. It is likely that this inhibition is also responsible for the anti-epileptic action of gabapentin.
There is some evidence that gabapentin also acts on adenosine receptors and voltage-gated potassium channels, though the clinical relevance of its action at these sites is unclear.
- Primary indication
- In the United States, gabapentin is officially indicated for the treatment of postherpetic neuralgia in adults and for the adjunctive treatment of partial-onset seizures, with or without secondary generalization, in patients 3 years of age...Curator reviewed · 7 structured indications
- Formula / weight
- C9H17NO2 · 171.2368 g/mol (avg)
- First approval
- Canada, 1998 · United States, 1993
- Code names
- CI-945 · DM-1796 · GOE-3450
- Brand names
- Gabarone
- Gralise
- Neurontin
- Relgaabi
Resolves to
UGJMXCAKCUNAIE-UHFFFAOYSA-NSMILESNCC1(CC(O)=O)CCCCC1What you can answer from here — as of September 20, 2026
Which drugs share a target with Gabapentin, and which of those have an active Phase 3 trial?